Tris Pharma to Present New Safety Data for First-In-Class Investigational Pain Therapy and Host Symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain
July 30 2024 - 8:30AM
Business Wire
– Presentation will highlight new safety data
on cebranopadol, first-in-class compound with a novel mechanism of
action to treat pain –
– Tris Pharma to host symposium on dual-NMR
agonists, a promising new mechanism of action in treating pain,
featuring leading industry researchers –
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical
company focused on attention deficit hyperactivity disorder (ADHD),
pain, addiction and neurological disorders, today announced that
the company will present data from its first-in-class, late-stage
investigational pain therapy with a novel mechanism of action,
cebranopadol, at the upcoming International Association for the
Study of Pain (IASP) 2024 World Congress on Pain, taking place
August 5-9, 2024, in Amsterdam.
“I am inspired to see the rise in interest, funding and research
into the development of novel treatment options for the millions of
people who suffer daily from debilitating pain that impacts their
quality of life,” said Ketan Mehta, founder and CEO at Tris Pharma.
“Our team has been working with urgency to advance cebranopadol, a
first-in-class investigational pain therapy with a novel mechanism
of action, through clinical studies with the goal of offering
physicians an effective treatment option that they can confidently
prescribe and patients feel is safe. We look forward to
collaborating with the pain community at IASP 2024 and sharing our
latest findings.”
Cebranopadol is the first and only dual nociceptin/orphanin FQ
peptide (NOP) receptor and µ-opioid peptide (MOP) receptor
(dual-NMR) agonist in development to treat moderate-to-severe pain.
Dual-NMR agonist compounds have the potential to deliver
gold-standard pain relief with a strong safety profile because they
mimic the body’s natural pain-modulation processes by synergizing
the analgesic and safety characteristics of the NOP receptor with
the analgesic advantages of the MOP receptor. Tris Pharma plans to
share important news regarding its Phase 3 clinical trials in the
near future.
Symposium Highlighting Novel Pain Mechanism Tris Pharma
will host a symposium featuring a series of presentations focused
on dual-NMR agonists, a promising new mechanism of action in
treating pain, and its potential to overcome the shortfalls of
opioids for moderate-to-severe pain. The symposium will be
presented as part of the congress by leading scientists with
extensive experience in the research and development of novel pain
therapies.
Details of the symposium are as follows:
Symposium: Break the Mold in Pain
Biology: The Promise of a New Mechanism that May Overcome the
Shortfalls of Current Moderate to Severe Pain Medications
Presenters: Charles E. Argoff, MD, Albany Medical College;
Roberto Ciccocioppo, PhD, University of Camerino; Jeffrey Gudin,
MD, University of Miami Miller School of Medicine Location:
RAI Amsterdam Convention Centre, Elicium I Date and Time:
August 6, 12:45 – 1:45 p.m. CEST
At IASP 2024 Tris Pharma will be present at Booth #316 where
company executives will be available to provide additional
information and data presented at the congress.
About Cebranopadol (TRN-228) Cebranopadol is the first and only
investigational dual nociceptin/orphanin FQ peptide (NOP) receptor
and µ-opioid peptide (MOP) receptor (dual-NMR) agonist for the
treatment of moderate-to-severe pain, as well as opioid use
disorder (OUD). Cebranopadol offers a first of its kind and novel
mechanism of action that takes advantage of the inherent properties
of the NOP receptor, which has demonstrated both the potential to
lessen the risk of misuse while still providing effective pain
relief, and the potential to block drugs of abuse from producing
drug-seeking behaviors. The FDA has granted Fast Track Designation
to cebranopadol for chronic low back pain. Cebranopadol’s profile
has been well-characterized in pain management studies, and if
approved, it could become the first and only pain-relief therapy
with the demonstrated ability to provide efficacy equivalent to
opioids with significantly less risk for misuse or risk of physical
dependence, addiction or overdose.
About Tris Pharma Tris Pharma is a privately held,
innovation-driven biopharmaceutical company that is applying its
drug development capabilities and proprietary technologies to
transform the treatment of ADHD, pain and neurological disorders,
including addiction and diseases of the central nervous system.
Tris is an established commercial organization with a robust
portfolio of best-in-class ADHD products and a promising pipeline
of differentiated, near-term drug candidates. More information is
available at www.trispharma.com and on LinkedIn
@TrisPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730108785/en/
Company Contact Cheryl Patnick Tris Pharma, Inc.
cpatnick@trispharma.com
Media Contact Laura Morgan Sam Brown, Inc. 951.333.9110
lauramorgan@sambrown.com